Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Seika Pharma Completes Acquisition of Outstanding Shares of Medreich
February 16, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
- AbbVie Files NDA for Chronic Hepatitis C Treatment in Japan
February 13, 2015
- Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
- Hypertension Most Commonly Treated Disease in Japan: Survey
February 12, 2015
- JCR Begins PI Study of Biosimilar for Fabry’s Disease Therapy
February 12, 2015
- Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
- Once-Monthly Oral Ibandronate Filed for Approval in Japan: Chugai, Taisho
February 12, 2015
- Daiichi Sankyo Launches Edoxaban in US
February 10, 2015
- Sandoz K.K. Names Mr Hasegawa as New President
February 10, 2015
- Takeda Cuts Costs of 19.5 Billion Yen by December 2014
February 9, 2015
- Ethical Drug Sales Up 2.5% in December: Crecon Report
February 9, 2015
- Astellas to Set Up New Panel on Global Management
February 6, 2015
- Eisai Discloses Option Rights for AD Treatment under Deal with Biogen Idec
February 6, 2015
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
- Daiichi Sankyo Initiates PIII Studies of Mirogabalin in Asia Including Japan
February 5, 2015
- Nipro’s Subsidiary to Build New Factory Eyeing Generic Market Expansion
February 5, 2015
- Wave of Downsizing (3): Mid-Sized Players Muted amid Industry’s Job-Shedding Drive
February 5, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…